STOCK TITAN

Corteva Inc Financials

CTVA
Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Corteva Inc (CTVA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CTVA FY2025

Margin expansion, disciplined balance-sheet use, and light reinvestment needs turned mostly steady sales into much stronger cash output.

From FY2022 to FY2025, gross margin expansion from 40.2% to 47.3% happened while sales stayed broadly flat, so the recovery was not mainly a top-line story. Free cash flow climbed from $267M to $2.8B, implying better unit economics plus easier working capital rather than simple volume growth.

Corteva's balance sheet looks internally funded: cash of $4.5B comfortably exceeds long-term debt of $1.7B. That matters because the company still returned over $1.5B through buybacks and dividends in FY2025 without pushing leverage higher, which suggests capital returns are being supported by operations rather than by stretching the balance sheet.

The business is also not especially capital intensive: capex stayed near $600M while operating cash flow reached $3.4B in FY2025. Because R&D rose to $1.5B and SG&A also increased, the improvement at the gross-profit level is what funds reinvestment, a useful sign that expense growth is not swallowing the gains from a better cost structure.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity Cash Flow Returns 38 / 100
Financial Health Score 38/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Corteva Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Growth
34

Corteva Inc's revenue grew a modest 2.9% year-over-year to $17.4B. This slow but positive growth earns a score of 34/100.

Leverage
83

Corteva Inc carries a low D/E ratio of 0.07, meaning only $0.07 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 83/100, indicating a strong balance sheet with room for future borrowing.

Liquidity
38

Corteva Inc's current ratio of 1.43 indicates adequate short-term liquidity, earning a score of 38/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow
73

Corteva Inc converts 16.2% of revenue into free cash flow ($2.8B). This strong cash generation earns a score of 73/100.

Piotroski F-Score Strong
7/9

Corteva Inc passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed
3.11x

For every $1 of reported earnings, Corteva Inc generates $3.11 in operating cash flow ($3.4B OCF vs $1.1B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$17.4B
YoY+2.9%
5Y CAGR+4.1%

Corteva Inc generated $17.4B in revenue in fiscal year 2025. This represents an increase of 2.9% from the prior year.

EBITDA
N/A
Net Income
$1.1B
YoY+20.6%
5Y CAGR+9.9%

Corteva Inc reported $1.1B in net income in fiscal year 2025. This represents an increase of 20.6% from the prior year.

EPS (Diluted)
$1.60
YoY+23.1%
5Y CAGR+11.9%

Corteva Inc earned $1.60 per diluted share (EPS) in fiscal year 2025. This represents an increase of 23.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow
$2.8B
YoY+81.8%
5Y CAGR+12.1%

Corteva Inc generated $2.8B in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 81.8% from the prior year.

Cash & Debt
$4.5B
YoY+45.6%
5Y CAGR+5.1%

Corteva Inc held $4.5B in cash against $1.7B in long-term debt as of fiscal year 2025.

Dividends Per Share
$0.70
YoY+6.1%
5Y CAGR+6.1%

Corteva Inc paid $0.70 per share in dividends in fiscal year 2025. This represents an increase of 6.1% from the prior year.

Shares Outstanding
673M
YoY-1.9%
5Y CAGR-2.0%

Corteva Inc had 673M shares outstanding in fiscal year 2025. This represents a decrease of 1.9% from the prior year.

Margins & Returns

Gross Margin
47.3%
YoY+3.6pp
5Y CAGR+7.1pp

Corteva Inc's gross margin was 47.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.6 percentage points from the prior year.

Operating Margin
N/A
Net Margin
6.3%
YoY+0.9pp
5Y CAGR+1.5pp

Corteva Inc's net profit margin was 6.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 0.9 percentage points from the prior year.

Return on Equity
4.5%
YoY+0.7pp
5Y CAGR+1.8pp

Corteva Inc's ROE was 4.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 0.7 percentage points from the prior year.

Capital Allocation

R&D Spending
$1.5B
YoY+5.1%
5Y CAGR+5.2%

Corteva Inc invested $1.5B in research and development in fiscal year 2025. This represents an increase of 5.1% from the prior year.

Share Buybacks
$1.1B
YoY+6.1%
5Y CAGR+31.2%

Corteva Inc spent $1.1B on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 6.1% from the prior year.

Capital Expenditures
$591.0M
YoY-1.0%
5Y CAGR+4.5%

Corteva Inc invested $591.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 1.0% from the prior year.

CTVA Income Statement

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Revenue $4.9B+25.4% $3.9B+49.4% $2.6B-59.4% $6.5B+46.2% $4.4B+11.0% $4.0B+71.0% $2.3B-61.9% $6.1B
Cost of Revenue $2.4B+5.2% $2.3B+37.1% $1.6B-43.9% $2.9B+25.2% $2.3B-6.2% $2.5B+59.5% $1.6B-46.4% $2.9B
Gross Profit $2.5B+53.0% $1.7B+70.0% $974.0M-72.4% $3.5B+69.8% $2.1B+40.0% $1.5B+94.7% $761.0M-76.2% $3.2B
R&D Expenses $341.0M-17.4% $413.0M+17.7% $351.0M-6.4% $375.0M+11.9% $335.0M-8.2% $365.0M+4.9% $348.0M-2.5% $357.0M
SG&A Expenses $877.0M+2.0% $860.0M+18.6% $725.0M-37.3% $1.2B+53.9% $751.0M+2.2% $735.0M+9.5% $671.0M-36.3% $1.1B
Operating Income N/A N/A N/A N/A N/A N/A N/A N/A
Interest Expense $36.0M N/A N/A $52.0M+44.4% $36.0M-40.0% $60.0M-9.1% $66.0M0.0% $66.0M
Income Tax $133.0M+1800.0% $7.0M+111.3% -$62.0M-114.7% $422.0M+260.7% $117.0M-15.2% $138.0M+221.1% -$114.0M-140.4% $282.0M
Net Income $720.0M+230.4% -$552.0M-72.5% -$320.0M-124.4% $1.3B+101.5% $652.0M+1690.2% -$41.0M+92.2% -$524.0M-149.8% $1.1B
EPS (Diluted) $1.07 N/A $-0.47-124.5% $1.92+102.1% $0.95 N/A $-0.76-150.3% $1.51

CTVA Balance Sheet

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Total Assets $42.7B-0.3% $42.8B+1.5% $42.2B+1.1% $41.8B-0.9% $42.1B+3.2% $40.8B-2.6% $41.9B+1.1% $41.5B
Current Assets $17.4B+0.3% $17.3B+5.5% $16.4B+2.7% $16.0B-3.5% $16.6B+9.9% $15.1B-3.5% $15.6B+1.9% $15.4B
Cash & Equivalents $2.0B-56.6% $4.5B+80.2% $2.5B+21.5% $2.1B+2.8% $2.0B-35.4% $3.1B+28.3% $2.4B+31.6% $1.8B
Inventory $5.2B-8.2% $5.7B+6.7% $5.3B+23.0% $4.3B-15.9% $5.1B-5.5% $5.4B-4.3% $5.7B+16.0% $4.9B
Accounts Receivable $7.3B+48.8% $4.9B-3.3% $5.0B-15.3% $6.0B-11.9% $6.8B+52.1% $4.4B+4.4% $4.3B-17.6% $5.2B
Goodwill $10.4B-0.5% $10.5B-0.4% $10.5B-0.1% $10.5B+1.8% $10.3B-0.7% $10.4B-2.1% $10.6B+1.3% $10.5B
Total Liabilities $18.4B-1.9% $18.7B+10.1% $17.0B+7.1% $15.8B-11.1% $17.8B+4.7% $17.0B-0.8% $17.2B+5.4% $16.3B
Current Liabilities $11.9B-2.2% $12.1B+16.4% $10.4B+9.5% $9.5B-17.1% $11.5B+10.5% $10.4B-0.4% $10.4B+16.4% $9.0B
Long-Term Debt $1.7B-0.2% $1.7B-0.1% $1.7B+0.1% $1.7B-5.9% $1.8B-8.2% $2.0B-1.1% $2.0B-20.1% $2.5B
Total Equity $24.4B+0.9% $24.1B-4.3% $25.2B-2.7% $25.9B+6.7% $24.3B+2.1% $23.8B-3.8% $24.7B-1.8% $25.2B
Retained Earnings $436.0M+750.7% -$67.0M-108.0% $834.0M-45.6% $1.5B+161.0% $587.0M+967.3% $55.0M-43.9% $98.0M-90.1% $992.0M

CTVA Cash Flow Statement

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Operating Cash Flow -$2.9B-166.1% $4.4B+2166.8% $193.0M-79.6% $947.0M+144.9% -$2.1B-150.5% $4.2B+3110.0% $130.0M-71.2% $451.0M
Capital Expenditures $81.0M-63.5% $222.0M+41.4% $157.0M+33.1% $118.0M+25.5% $94.0M-48.1% $181.0M+17.5% $154.0M+35.1% $114.0M
Free Cash Flow -$3.0B-171.6% $4.2B+11436.1% $36.0M-95.7% $829.0M+137.6% -$2.2B-155.2% $4.0B+16733.3% -$24.0M-107.1% $337.0M
Investing Cash Flow -$77.0M+59.0% -$188.0M-19.7% -$157.0M+4.3% -$164.0M-382.4% -$34.0M+72.4% -$123.0M+23.6% -$161.0M-360.0% -$35.0M
Financing Cash Flow $389.0M+117.7% -$2.2B-698.9% $367.0M+145.4% -$808.0M-181.2% $995.0M+129.8% -$3.3B-638.9% $619.0M+349.6% -$248.0M
Dividends Paid $121.0M0.0% $121.0M-0.8% $122.0M+5.2% $116.0M0.0% $116.0M-1.7% $118.0M+0.9% $117.0M+5.4% $111.0M
Share Buybacks $250.0M-16.9% $301.0M+20.4% $250.0M0.0% $250.0M-7.4% $270.0M+7.1% $252.0M-0.4% $253.0M+0.4% $252.0M

CTVA Financial Ratios

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Gross Margin 51.6%+9.3pp 42.4%+5.1pp 37.2%-17.4pp 54.6%+7.6pp 47.0%+9.7pp 37.3%+4.5pp 32.7%-19.5pp 52.3%
Operating Margin N/A N/A N/A N/A N/A N/A N/A N/A
Net Margin 14.7%+28.8pp -14.1%-1.9pp -12.2%-32.6pp 20.3%+5.6pp 14.8%+15.8pp -1.0%+21.5pp -22.5%-39.8pp 17.2%
Return on Equity 3.0%+5.2pp -2.3%-1.0pp -1.3%-6.3pp 5.1%+2.4pp 2.7%+2.9pp -0.2%+1.9pp -2.1%-6.3pp 4.2%
Return on Assets 1.7%+3.0pp -1.3%-0.5pp -0.8%-3.9pp 3.1%+1.6pp 1.6%+1.7pp -0.1%+1.1pp -1.3%-3.8pp 2.5%
Current Ratio 1.47+0.0 1.43-0.1 1.58-0.1 1.68+0.2 1.440.0 1.45-0.0 1.50-0.2 1.72
Debt-to-Equity 0.070.0 0.070.0 0.070.0 0.070.0 0.070.0 0.080.0 0.08-0.0 0.10
FCF Margin -60.6%-166.8pp 106.2%+104.8pp 1.4%-11.5pp 12.8%+62.7pp -49.9%-150.2pp 100.4%+101.4pp -1.0%-6.5pp 5.5%

Similar Companies

Frequently Asked Questions

Corteva Inc (CTVA) reported $17.4B in total revenue for fiscal year 2025. This represents a 2.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Corteva Inc (CTVA) revenue grew by 2.9% year-over-year, from $16.9B to $17.4B in fiscal year 2025.

Yes, Corteva Inc (CTVA) reported a net income of $1.1B in fiscal year 2025, with a net profit margin of 6.3%.

Corteva Inc (CTVA) reported diluted earnings per share of $1.60 for fiscal year 2025. This represents a 23.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

As of fiscal year 2025, Corteva Inc (CTVA) had $4.5B in cash and equivalents against $1.7B in long-term debt.

Corteva Inc (CTVA) had a gross margin of 47.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Corteva Inc (CTVA) had a net profit margin of 6.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Yes, Corteva Inc (CTVA) paid $0.70 per share in dividends during fiscal year 2025.

Corteva Inc (CTVA) has a return on equity of 4.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Corteva Inc (CTVA) generated $2.8B in free cash flow during fiscal year 2025. This represents a 81.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Corteva Inc (CTVA) generated $3.4B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Corteva Inc (CTVA) had $42.8B in total assets as of fiscal year 2025, including both current and long-term assets.

Corteva Inc (CTVA) invested $591.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Corteva Inc (CTVA) invested $1.5B in research and development during fiscal year 2025.

Yes, Corteva Inc (CTVA) spent $1.1B on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Corteva Inc (CTVA) had 673M shares outstanding as of fiscal year 2025.

Corteva Inc (CTVA) had a current ratio of 1.43 as of fiscal year 2025, which is considered adequate.

Corteva Inc (CTVA) had a debt-to-equity ratio of 0.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Corteva Inc (CTVA) had a return on assets of 2.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Corteva Inc (CTVA) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Corteva Inc (CTVA) has an earnings quality ratio of 3.11x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Corteva Inc (CTVA) scores 38 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top